High Content Screening as High Quality Assay for Biological Evaluation of Photosensitizers In Vitro

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Vaz, Gisela M F ^a   Paszko, Edyta ^a   Davies, Anthony M ^a   Senge, Mathias O ^a,b  

^a ST JAMES S HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PHOTOSENSITIZING AGENT; PORPHYRIN; TEMOPORFIN;

ACCURACY; ARTICLE; CANCER CELL; CELL COUNT; CELL DEATH; CELL PROLIFERATION; COLORIMETRY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SCREENING; ESOPHAGUS CANCER; HIGH CONTENT SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SCREENING TEST; VALIDITY;

CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR IMAGING; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SMALL MOLECULE LIBRARIES;

EID: 84880772898     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070653     Document Type: Article

References (51)

1. Dragunow M, (2008) High-content analysis in neuroscience. Nat Rev Neurosci 9: 779-788.
2. Shun TY, Lazo JS, Sharlow ER, Johnston PA, (2011) Identifying actives from HTS data sets: Practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen 16: 1-14.
3. Dove A, (2003) Screening for content-the evolution of high throughput. Nat Biotech 21: 859-864.
4. Abraham VC, Taylor DL, Haskins JR, (2004) High content screening applied to large-scale cell biology. Trends Biotechnol 22: 15-22.
5. Haney SA, LaPan P, Pan J, Zhang J, (2006) High-content screening moves to the front of the line. Drug Discov Today 11: 889-894.
6. Xu JJ, Diaz D, O'Brien PJ, (2004) Applications of cytotoxicity assays and pre-lethal mechanistic assays for assessment of human hepatotoxicity potential. Chem Biol Interact 150: 115-128.
7. Lieggi NT, Edvardsson A, O'Brien PJ, (2010) Translation of novel anti-cancer cytotoxicity biomarkers detected with high content analysis from an in vitro predictive model to an in vivo cell model. Toxicol in Vitro 24: 2063-2071.
8. Brown SB, Brown EA, Walker I, (2004) The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 5: 497-508.
9. Dougherty TJ, (1993) Photodynamic Therapy. Photochem Photobiol 58: 895-900.
10. Agostinis P, Berg K, Cengel KA, Foster TH, Girotti AW, Gollnick SO, et al. (2011) Photodynamic therapy of cancer: An update. CA Cancer J Clin 61: 250-281.
11. Nyman ES, Hynninen PH, (2004) Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B:Biol 73: 1-28.
12. Ethirajan M, Chen Y, Joshi P, Pandey RK, (2011) The role of porphyrin chemistry in tumor imaging and photodynamic therapy. Chem Soc Rev 40: 340-362.
13. Emma H. (2003) New drug enters PDT clinical trials. Lancet Oncol 4, 136.
14. Fayter D, Corbett M, Heirs M, Fox D, Eastwood A, (2010) A systematic review of photodynamic therapy in the treatment of precancerous skin conditions, Barrett's oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin. Health Technol Assess 14: 1-129.
15. Henderson BW, Bellnier DA, Greco WR, Sharma A, Pandey RK, et al. (1997) An in Vivo Quantitative Structure-Activity Relationship for a Congeneric Series of Pyropheophorbide Derivatives as Photosensitizers for Photodynamic Therapy. Cancer Res 57: 4000-4007.
16. Huang YY, Mroz P, Zhiyentayev T, Sharma SK, Balasubramanian T, et al. (2010) In vitro photodynamic therapy and quantitative structure-activity relationship studies with stable synthetic near-infrared-absorbing bacteriochlorin photosensitizers. J Med Chem 53: 4018-4027.
17. Paszko E, Vaz GM, Ehrhardt C, Senge MO, (2013) Transferrin conjugation does not increase the efficiency of liposomal Foscan during in vitro photodynamic therapy of oesophageal cancer. Eur J Pharm Sci 48: 202-210.
18. Altorki N, Schwartz GK, Blundell M, Davis BM, Kelsen DP, et al. (1993) Characterization of cell lines established from human gastric-esophageal adenocarcinomas. Biologic phenotype and invasion potential. Cancer 72: 649-657.
19. Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR, (1997) Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 75: 258-263.
20. Bonnett R, White RD, Winfield UJ, Berenbaum MC, (1989) Hydroporphyrins of the meso-tetra(hydroxyphenyl)porphyrin series as tumor photosensitizers. Biochem J 261: 277-280.
21. Feest C (2009) Photophysical characterisation and in vitro testing of novel tetraphenylporphyrin derivative with respect to their application in photodynamic therapy. Diploma thesis, Humboldt-Universität Berlin, Berlin, Germany.
22. Tim M, (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Meth. 65: 55-63.
23. Tada H, Shiho O, Kuroshima K-i, Koyama M, Tsukamoto K, (1986) An improved colorimetric assay for interleukin 2. J Immunol Meth 93: 157-165.
24. Freeley M, Bakos G, Davies A, Kelleher D, Long A, et al. (2010) A High-Content Analysis Toolbox Permits Dissection of Diverse Signaling Pathways for T Lymphocyte Polarization. J Biomol Screen 15: 541-555.
25. Ramirez CN, Ozawa T, Takagi T, Antczak C, Shum D, et al. (2010) Validation of a High-Content Screening Assay Using Whole-Well Imaging of Transformed Phenotypes. Assay Drug Dev Technol 9: 247-261.
26. Barbaric I, Jones M, Harley DJ, Gokhale PJ Andrews PW, (2011) High-Content Screening for Chemical Modulators of Embryonal Carcinoma Cell Differentiation and Survival. J Biomol Screen 16: 603-617.
27. Frisoli JK, Tudor EG, Flotte TJ, Hasan T, Deutsch TF, et al. (1993) Pharmacokinetics of a Fluorescent Drug Using Laser-induced Fluorescence. Cancer Res 53: 5954-5961.
28. Martin C, Walker J, Rothnie A, Callaghan R, (2003) The expression of P-glycoprotein does influence the distribution of novel fluorescent compounds in solid tumour models. Br J Cancer. 89: 1581-1589.
29. Kalayda GV, Jansen BAJ, Wielaard P, Tanke HJ, Reedijk J, (2005) Dinuclear platinum anticancer complexes with fluorescent N,N′-bis(aminoalkyl)-1,4-diaminoanthraquinones: cellular processing in two cisplatin-resistant cell lines reflects the differences in their resistance profiles. J Biol Inorg Chem 10: 305-315.
30. Senge MO, Brandt JC, (2011) Temoporfin (Foscan®, 5,10,15,20-Tetra(m-hydroxyphenyl)chlorin), a Second Generation Photosensitizer. Photochem Photobiol 87: 1240-1296.
31. Senge MO, (2012) mTHPC-A drug on its way from second to third generation photosensitizer? Photodiagn Photodyn Ther 9: 170-179.
32. Rockett JC, Larkin K, Darnton SJ, Morris AG, Matthews HR, (1997) Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br J Cancer 75: 258-263.
33. Abdel-Latif MM, O'Riordan J, Windle HJ, Carton E, Ravi N, et al. (2004) NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg 239: 491-500.
34. Duggan SP, Gallagher WM, Fox EJP, Abdel-Latif MM, Reynolds JV, et al. (2006) Low pH induces co-ordinate regulation of gene expression in oesophageal cells. Carcinogenesis 27: 319-327.
35. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB, (1987) Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing. Cancer Res 47: 936-942.
36. Morgan DML (1998) Tetrazolium (MTT) Assay for Cellular Viability and Activity, Polyamine Protocols. Morgan, D.M.L. Totowa, NJ, USA.
37. Hamid R, Rotshteyn Y, Rabadi L, Parikh R, Bullock P, (2004) Comparison of alamar blue and MTT assays for high through-put screening. Toxicol in Vitro 18: 703-710.
38. Bortner CD, Cidlowski JA, (2002) Apoptotic volume decrease and the incredible shrinking cell. Cell Death Differ 9: 1307-1310.
39. Dove A, (2003) Screening for content-the evolution of high throughput. Nat Biotech 21: 859-864.
40. Kiesslich T, Berlanda J, Plaetzer K, Krammer B, Berr F, (2007) Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan® and Foslip® based photodynamic treatment in human biliary tract cancer cell lines. Photochem Photobiol Sci 6: 619-627.
41. Marchal S, Francois A, Dumas D, Guillemin F, Bezdetnaya L, (2007) Relationship between subcellular localisation of Foscan® and caspase activation in photosensitised MCF-7 cells. Br J Cancer. 96: 944-951.
42. Teiten MH, Bezdetnaya L, Morliere P, Santu R, Guillemin F, (2003) Endoplasmic reticulum and Golgi apparatus are the preferential sites of Foscan localisation in cultured tumour cells. Br J Cancer. 88: 146-152.
43. Lassalle H-P, Wagner M, Bezdetnaya L, Guillemin F, Schneckenburger H, (2008) Fluorescence imaging of Foscan® and Foslip in the plasma membrane and in whole cells. J Photochem Photobiol B:Biol 92 47-53: 39.
44. Berenbaum MC, Akande SL, Bonnett R, Kaur H, Ioannou S, et al. (1986) meso-Tetra(hydroxyphenyl) porphyrins, a new class of potent tumor photosensitizers with favorable selectivity. Br J Cancer 54: 717-725.
45. Abraham VC, Towne DL, Waring JF, Warrior U, Burns DJ, (2008) Application of a High-Content Multiparameter Cytotoxicity Assay to Prioritize Compounds Based on Toxicity Potential in Humans. J Biomol Screen 13: 527-537.
46. Wiehe A, Shaker YM, Brandt JC, Mebs S, Senge MO, (2005) Lead structures for applications in photodynamic therapy. Part 1: Synthesis and variation of m-THPC (Temoporfin) related amphiphilic A(2)BC-type porphyrins. Tetrahedron 61: 5535-5564.
47. Senge MO, Shaker YM, Pintea M, Ryppa C, Hatscher SS, et al. (2010) Synthesis of meso-Substituted ABCD-Type Porphyrins by Functionalization Reactions. Eur J Org Chem: 237-258.
48. Thomas S, Metcalfe P, Walker P, Tsaioun K, (2011) Filtering toxicity from the pipeline: The role of high content toxicology in early identification of toxic liabilities. Toxicol Lett 205: S177-S178.
49. Helmy IM, Azim AM (2012) Efficacy of ImageJ in the assessment of apoptosis. Diagn Pathol 7: Art.No 15.
50. Filippi-Chiela EC, Oliveira MM, Jurkovski B, Callegari-Jacques SM, da Silva VD, et al. (2012) Nuclear morphometric analysis (NMA): screening of senescence, apoptosis and nuclear irregularities. PLoS ONE 7: e42522.
51. Swinney DC Anthony J, (2011) How were new medicines discovered? Nat Rev Drug Discov 10: 507-519.